ATE295853T1 - Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen - Google Patents

Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE295853T1
ATE295853T1 AT98962665T AT98962665T ATE295853T1 AT E295853 T1 ATE295853 T1 AT E295853T1 AT 98962665 T AT98962665 T AT 98962665T AT 98962665 T AT98962665 T AT 98962665T AT E295853 T1 ATE295853 T1 AT E295853T1
Authority
AT
Austria
Prior art keywords
ptx3
pharmaceutical compositions
compositions containing
long pentraxin
containing long
Prior art date
Application number
AT98962665T
Other languages
English (en)
Inventor
Barbara Bottazzi
Martino Introna
Alberto Mantovani
Annunciata Vecchi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE295853T1 publication Critical patent/ATE295853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98962665T 1997-12-19 1998-12-16 Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen ATE295853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000796A IT1298487B1 (it) 1997-12-19 1997-12-19 Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
PCT/IT1998/000364 WO1999032516A2 (en) 1997-12-19 1998-12-16 Pharmaceutical compositions containing the long pentraxin ptx3

Publications (1)

Publication Number Publication Date
ATE295853T1 true ATE295853T1 (de) 2005-06-15

Family

ID=11405409

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962665T ATE295853T1 (de) 1997-12-19 1998-12-16 Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen

Country Status (13)

Country Link
US (1) US8003109B2 (de)
EP (1) EP1034185B1 (de)
JP (1) JP4173633B2 (de)
KR (1) KR100560085B1 (de)
AT (1) ATE295853T1 (de)
AU (1) AU756974B2 (de)
CA (1) CA2315277C (de)
DE (1) DE69830251T2 (de)
ES (1) ES2242309T3 (de)
IT (1) IT1298487B1 (de)
NZ (1) NZ505063A (de)
PT (1) PT1034185E (de)
WO (1) WO1999032516A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US20040198655A1 (en) * 2001-08-03 2004-10-07 Alberto Mantovani Use of long pentraxin ptx3 for treating female infertility
US7041648B2 (en) 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
JP5427415B2 (ja) * 2006-01-24 2014-02-26 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Ｆｇｆ２結合性ペプチドおよびそれらの使用
EP1832295A1 (de) 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
PT2012816E (pt) * 2006-05-02 2012-08-17 Sigma Tau Ind Farmaceuti Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus
WO2009095403A1 (en) * 2008-01-29 2009-08-06 Tecnogen S.P.A. Expression system and uses thereof for the production of human long pentraxin 3
HRP20130947T1 (hr) 2009-07-29 2013-11-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Poboljšani sustav za eksprimiranje ljudskog dugog pentraksina 3 i njegova upotreba
KR101305515B1 (ko) 2011-06-10 2013-09-06 경북대학교 산학협력단 펜트락신 3 단백질의 파킨슨 질환 진단 용도
WO2013191280A1 (ja) * 2012-06-22 2013-12-27 国立大学法人 東京大学 全身性炎症反応症候群の治療又は予防剤
TWI528969B (zh) * 2013-06-07 2016-04-11 國立成功大學 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途
TWI531375B (zh) 2015-05-29 2016-05-01 國立成功大學 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物
CN105132459B (zh) * 2015-09-14 2019-01-29 武汉市星熠艾克生物医药有限责任公司 人类ptx3重组蛋白的制备方法及应用
EP4103592A4 (de) * 2020-02-12 2024-01-10 BioTissue Holdings Inc. Verfahren zur abtötung oder hemmung des wachstums von krebszellen
US20230227511A1 (en) * 2020-05-14 2023-07-20 Nippon Medical School Foundation Therapeutic or preventive agent for infectious disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
JPH06506195A (ja) * 1991-01-14 1994-07-14 ニューヨーク　ユニバシテイ サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用
IT1254687B (it) * 1992-04-14 1995-09-28 Italfarmaco Spa Gene inducibile da citochine
US6210941B1 (en) * 1997-06-27 2001-04-03 The Trustees Of Boston University Methods for the detection and isolation of proteins
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5939423A (en) * 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US7041648B2 (en) * 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
US20040198655A1 (en) * 2001-08-03 2004-10-07 Alberto Mantovani Use of long pentraxin ptx3 for treating female infertility
US20040137544A1 (en) * 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
WO2004094991A2 (en) 2003-04-23 2004-11-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (de) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
PT2012816E (pt) * 2006-05-02 2012-08-17 Sigma Tau Ind Farmaceuti Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus

Also Published As

Publication number Publication date
JP4173633B2 (ja) 2008-10-29
JP2002503642A (ja) 2002-02-05
EP1034185B1 (de) 2005-05-18
PT1034185E (pt) 2005-07-29
US20080015153A1 (en) 2008-01-17
WO1999032516A2 (en) 1999-07-01
KR20010033297A (ko) 2001-04-25
US8003109B2 (en) 2011-08-23
WO1999032516A3 (en) 1999-10-28
CA2315277C (en) 2010-02-23
AU1782999A (en) 1999-07-12
DE69830251D1 (de) 2005-06-23
KR100560085B1 (ko) 2006-03-13
ITRM970796A1 (it) 1999-06-19
IT1298487B1 (it) 2000-01-10
CA2315277A1 (en) 1999-07-01
NZ505063A (en) 2002-12-20
AU756974B2 (en) 2003-01-30
ES2242309T3 (es) 2005-11-01
EP1034185A2 (de) 2000-09-13
DE69830251T2 (de) 2005-10-27

Similar Documents

Publication Publication Date Title
ATE295853T1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
EP1637608A3 (de) Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
FI954966L (fi) Puutteellisia yhdistelmä-DNA-adenoviruksia kasvainten geeniterapiassa
DE10199011I2 (de) ASP-B28-Insulinkristalle.
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
NO984052D0 (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
ATE355385T1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
ATE286127T1 (de) Verabreichung der therapeutischen proteine durch implantation der genetischen modifizierten zellen in das omentum
ATE309354T1 (de) Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1034185

Country of ref document: EP